SCHEMBL29432750

SCHEMBL29432750

O=C(c1ccccc1F)N1CCC2CCC1CN2Cc1c(-c2ccc(Cl)cc2)nc2ccccn12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ KCNK3 O14649 20/20 1.00
▸ KCNK9 Q9NPC2 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20588394 1.00 KCNK3 (1.00) KCNK3KCNK9
SCHEMBL19807481 0.94 KCNK3 (0.89) KCNK3KCNK9
SCHEMBL22001644 0.89 KCNK3 (1.00) KCNK3KCNK9
SCHEMBL20587802 0.88 KCNK3 (1.00) KCNK3KCNK9
SCHEMBL29458025 0.88 KCNK3 (1.00) KCNK3KCNK9
SCHEMBL19807738 0.87 KCNK3 (0.78) KCNK3KCNK9
SCHEMBL22635898 0.87 KCNK3 (0.77) KCNK3KCNK9
SCHEMBL19807710 0.86 KCNK3 (0.76) KCNK3KCNK9
SCHEMBL29432795 0.86 KCNK3 (1.00) KCNK3KCNK9
SCHEMBL20587932 0.86 KCNK3 (1.00) KCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4452264-A1 COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA Bayer Aktiengesellschaft (DE) 2024-10-30 — — EP disclosed
EP-4452246-A1 COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA Bayer Aktiengesellschaft (DE) 2024-10-30 — — EP disclosed
EP-4452263-A1 COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A P2X3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA Bayer Aktiengesellschaft (DE) 2024-10-30 — — EP disclosed
CN-118785904-A Conjugates of TASK1/3 channel blockers and P2X3 receptor antagonists for the treatment of sleep apnea 拜耳公司 2024-10-15 — — CN disclosed
CN-118541153-A Conjugates of a TASK1/3 channel blocker and a norepinephrine reuptake inhibitor for the treatment of sleep apnea 拜耳公司 2024-08-23 — — CN disclosed
CN-118434415-A Conjugates of TASK1/3 channel blockers and muscarinic receptor antagonists for the treatment of sleep apnea 拜耳公司 2024-08-02 — — CN disclosed
WO-2023118126-A1 COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA BAYER AKTIENGESELLSCHAFT (DE) 2023-06-29 — — WO disclosed
WO-2023118102-A1 COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA BAYER AKTIENGESELLSCHAFT (DE) 2023-06-29 — — WO disclosed
EP-4175954-A1 COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA Bayer Aktiengesellschaft (DE) 2023-05-10 — — EP disclosed
EP-3965762-A1 COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA Bayer Aktiengesellschaft (DE) 2022-03-16 — — EP disclosed
EP-3965766-A1 COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA Bayer Aktiengesellschaft (DE) 2022-03-16 — — EP disclosed
Send feedback